The congenital ®brosarcoma t(12;15)(p13;q25) rearrangement splices the ETV6 (TEL) gene on chromosome 12p13 in frame with the NTRK3 (TRKC) neurotrophin-3 receptor gene on chromosome 15q25. Resultant ETV6-NTRK3 fusion transcripts encode the helix ± loop ± helix (HLH) dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3. We show here that ETV6-NTRK3 homodimerizes and is capable of forming heterodimers with wild-type ETV6. Moreover, ETV6-NTRK3 has PTK activity and is autophosphorylated on tyrosine residues. To determine if the fusion protein has transforming activity, NIH3T3 cells were infected with recombinant retroviral vectors carrying the full-length ETV6-NTRK3 cDNA. These cells exhibited a transformed phenotype, grew macroscopic colonies in soft agar, and formed tumors in severe combined immunode®cient (SCID) mice. We hypothesize that chimeric proteins mediate transformation by dysregulating NTRK3 signal transduction pathways via ligand-independent dimerization and PTK activation. To test this hypothesis, we expressed a series of ETV6-NTRK3 mutants in NIH3T3 cells and assessed their transformation activities. Deletion of the ETV6 HLH domain abolished dimer formation with either ETV6 or ETV6-NTRK3, and cells expressing this mutant protein were morphologically non-transformed and failed to grow in soft agar. An ATP-binding mutant failed to autophosphorylate and completely lacked transformation activity. Mutants of the three NTRK3 PTK activationloop tyrosines had variable PTK activity but had limited to absent transformation activity. Of a series of signaling molecules well known to bind to wild-type NTRK3, only phospholipase-Cg (PLCg) associated with ETV6-NTRK3. However, a PTK active mutant unable to bind PLCg did not show defects in transformation activity. Our studies con®rm that ETV6-NTRK3 is a transforming protein that requires both an intact dimerization domain and a functional PTK domain for transformation activity. Oncogene (2000) 19, 906 ± 915.
Introduction
Congenital ®brosarcoma (CFS) is a cellular, mitotically active neoplasm of the soft tissues primarily aecting infants less than 1 year of age. It is a spindle cell sarcoma which may grow to enormous sizes and can cause considerable morbidity or mortality. Although CFS has a high propensity for local recurrence, this tumor is biologically unique among human sarcomas because of its overall survival of 80 ± 90% and metastatic rate of only 10% (Lamballe et al., 1993; Obermeier et al., 1993a) . Cytogenetic analyses of CFS cases have revealed nonrandom gains of chromosomes 8, 11, 17, and 20, with trisomy 11 being the most consistently observed alteration (Adam, 1990; Argyle, 1992; Con, 1994; Mandahl, 1989; Sankary, 1993; Speleman, 1989) . We have recently identi®ed a novel, recurrent t(12;15)(p13;q25) chromosome rearrangement in CFS that fuses ETV6 (TEL) on 12p13 to NTRK3 (TRKC) on 15q25 (Knezevich et al., 1998b) . This rearrangement, which can be detected in primary tumor specimens by reverse transcriptase-PCR assays (Knezevich et al., 1998b) , was present in all CFS cases analysed to date and was not detected in other ®broblastic lesions including benign infantile ®broma-tosis and adult-type ®brosarcoma (unpublished results). However, we and others have recently detected identical ETV6-NTRK3 fusion transcripts in the cellular form of congenital mesoblastic nephroma (CMN), a pediatric renal tumor which shows considerable histopathologic and clinical overlap with CFS (Knezevich et al., 1998a; Rubin et al., 1998) .
ETV6 is a member of the ETS family of transcription factors which may play a role in early hematopoiesis and angiogenesis (Baens et al., 1996; Edel, 1998; Kwiatkowski et al., 1998; O'Connor et al., 1998; Poirel et al., 1997; Wang et al., 1997 Wang et al., , 1998 . ETV6 was ®rst identi®ed as the fusion partner of PDGFRb in the t(5;12)(q33;p13) of chronic myelomonocytic leukemia (Golub et al., 1994) , and has since been identi®ed in a variety of gene fusions associated with hematopoietic malignancies. These include fusions with CBFA2 (AML1) (Golub et al., 1995; Romana et al., 1995) , ABL , MN1 (Buijs et al., 1995) , JAK2 (Lacronique et al., 1997; Peeters et al., 1997a) , STL (Suto et al., 1997) , MDS1/EVI1 (Peeters et al., 1997b) , CDX2 (Chase et al., 1999) , BTL (Cools et al., 1999) , and ACS2 (Yagasaki et al., 1999) . The well characterized ETV6-CBFA2 (TEL-AML1) fusion is often accompanied by deletion of the normal ETV6 allele on chromosome 12 (Cave et al., 1997) .
NTRK3 encodes the transmembrane surface receptor for neurotrophin-3 (NT-3) and mediates many aspects of growth and development in the central nervous system (Barbacid, 1995a; Conover and Yancopoulos, 1997; Ebadi et al., 1997; Ichaso et al., 1998; Lamballe et al., 1991; McGregor et al., 1994) . NTRK3 is activated by cell surface ligand-mediated oligomerization, which facilitates autophosphorylation of NTRK3 cytoplasmic tyrosine residues 516, 705, 709, 710, and 820 and subsequent kinase activation (Barbacid, 1994 (Barbacid, , 1995a Jing et al., 1992; Lemmon and Schlessinger, 1994) . Several adapter molecules and protein tyrosine kinase (PTK) substrates have been linked to NTRK3 signal transduction. Phosphorylated NTRK3 tyrosine-516 binds the adaptor protein Src-homology/collagen (SHC) via the SH2 domain of the latter (Guiton et al., 1995) , and is also the site of association with the p85 subunit of phosphoinositol-3' kinase (PI-3K) (Barbacid, 1994; Hallberg et al., 1998; Obermeier et al., 1993b) . Activated SHC recruits growth factor receptor bound protein 2 (GRB2), an adaptor protein, as well as the RAS guanine nucleotide exchange factor Son-ofsevenless (Sos) to activate the RAS-RAF1 pathway (Bon®ni et al., 1996; Downward, 1996) . Phosphorylated PI-3K mediates activation of the protein kinase B (Akt/PKB) pathway . Phosphorylated NTRK3 tyrosine-820 binds phospholipase-Cg (PLCg) (Lamballe et al., 1993; Obermeier et al., 1993a) , resulting in the activation of protein kinase C (PKC) (Berridge, 1993; Cockcroft and Thomas, 1992; Lee and Rhee, 1995; Nishizuka, 1995) . The suc1-associated neurotrophin factor target (SNT) protein was shown to bind to an NTRK3 juxtamembrane KFG sequence and become tyrosine phosphorylated (Peng et al., 1995; Rabin et al., 1993) . More recent studies on ®broblast growth factor (FGF) receptor-1 signaling indicate that phosphorylated SNT can associate with GRB2 and Sos in FGF-stimulated ®broblasts (Kouhara et al., 1997; Ong et al., 1996) . Other molecules known to associate with activated NTRK3 and potentially be involved in NTRK3 signaling include rAPS and SH2-Bb (Qian et al., 1998) .
The CFS t(12;15) rearrangement splices the ®rst ®ve exons of ETV6 to exons 6 ± 8 of NTRK3, creating a hybrid gene encoding the ETV6 helix ± loop ± helix (HLH) protein dimerization domain fused to the terminal 298 amino acids of NTRK3 (Knezevich et al., 1998b) . These NTRK3 residues include the PTK domain and C-terminus of NTRK3, but do not include the tyrosine-516 residue of NTRK3 which binds SHC and p85, nor the KFG sequence which binds SNT (Knezevich et al., 1998b) . We hypothesize that expression of the ETV6-NTRK3 fusion transcript is essential for the development of CFS tumors. Moreover, we propose that the HLH domain of ETV6-NTRK3 facilitates ligand-independent dimerization of the chimeric protein, and that subsequent constitutive PTK activation leads to oncogenesis by dysregulating known or novel NTRK3 signal-transduction pathways. We show here that ETV6-NTRK3 is an oncoprotein with potent transforming activity in NIH3T3 cells, and that intact HLH and PTK domains are both required for transformation.
Results

ETV6-NTRK3 transforms NIH3T3 cells
NIH3T3 cells were infected with recombinant retroviruses carrying either ETV6-NTRK3 cDNA or empty MSCVpac vector as a negative control. The predicted structure of the ETV6-NTRK3 protein encoded by the chimeric cDNA is shown in Figure 1 . Positive transformants were obtained by puromycin drug selection, and cell morphology was assessed after at least 1 week of growth. Cells infected with ETV6-NTRK3 exhibited a dramatically transformed phenotype compared to negative control cells (data not shown). The transformed cells possessed a high nucleus-to-cytoplasm ratio, their cell bodies strongly refracted light, and their growth was not inhibited by contact to other cells. ETV6-NTRK3-infected NIH3T3 cells were able to form macroscopic colonies after 16 ± 19 days of culture in soft agar (see Figure 2a ,c; Table  1 ). Colony formation was only slightly less than that observed with retrovirally infected NIH3T3 cells expressing the oncogenic Ewing sarcoma EWS-FLI1 fusion protein (see Table 1 ). Cells infected with vector alone failed to grow colonies even after 28 days of incubation (see Figure 2b ,d) and in subsequent long term growth. Expression of the predicted 73 and 68 kD ETV6-NTRK3 protein doublet in transformed NIH3T3 cells was veri®ed by Western blotting using Figure 1 Schematic representation of constructs made by sitedirected mutagenesis of ETV6-NTRK3. Non-mutated ETV6-NTRK3 is shown at the top. The HLH-domain deletion mutant, EN-DHLH, created by deleting amino acids 64 ± 177 representing part of the ETV6-NTRK3 HLH domain. The three activationloop tyrosines (Y) sequentially substituted with phenylalanine (F) in mutants EN-Y513F, EN-Y517F, and EN-Y518F, respectively. The activation-loop tyrosine triple mutant, EN-Yx3F, with all three activation-loop tyrosines mutated to phenylalanine. The ATP-binding site, lysine 380 (K), substituted with asparagine (N) in mutant EN-K380N. Tyrosine 628, the PLCg-binding site, mutated to a threonine, glutamine, or glutamic acid residue in the EN-Y628T, EN-Y628Q, or EN-Y628E mutants, respectively a-TrkC (C-14), while this doublet was not present in control cells infected with vector alone (see lanes 1 and 7, left panel, Figure 2f ). Therefore, ETV6-NTRK3 encodes a chimeric protein with strong transforming potential in NIH3T3 cells.
ETV6-NTRK3-mediated transformation requires both the ETV6 HLH and the NTRK3 PTK domains
The HLH protein dimerization domain of ETV6 was deleted to assess the potential role of oligomerization in ETV6-NTRK3 transformation. Retrovirally infected NIH3T3 cells expressing the HLH-mutant, EN-DHLH (see Figure 1) , were morphologically identical to those infected with vector alone; that is, they did not exhibit a transformed phenotype (data not shown). Moreover, in soft agar assays, EN-DHLH-infected NIH3T3 cells failed to form colonies even after 4 weeks of incubation (see Table 1 ). These results indicate that the HLH domain is essential for ETV6-NTRK3 transformation of NIH3T3 cells. Protein expression at levels similar to ETV6-NTRK3 was veri®ed by immunoprecipitation using a-TrkC (C-14) antibodies (see lanes 2 and 3, right panel, Figure 2f ).
To assess the role of the PTK domain in transformation, NIH3T3 cells were infected with recombinant viruses expressing ETV6-NTRK3 proteins with tyrosine-to-phenylalanine mutations in each of the three activation loop tyrosines (designated EN-Y513F, EN-Y517F, and EN-Y518F, respectively) known to be essential for PTK activity (Barbacid, 1994; Lamballe et al., 1993; Tsoulfas et al., 1993; Valenzuela et al., 1993) , as well as a mutant in which all three tyrosines were converted to phenylalanine (EN-Yx3F) (see Figure 1) . We also constructed a kinase-inactive ETV6-NTRK3 mutant in which the ATP-binding lysine 380 (NTRK3 lysine 572) (Lamballe et al., 1991; Mitra, 1991) was converted to asparagine, designated EN-K380N (Figure 1) . Transformation activity was assessed by cell morphology and ability to grow in soft agar. NIH3T3 Table 1 ). Cells expressing the EN-Y517F and EN-Y518F mutants exhibited a semi-transformed phenotype (data not shown); these cells did not form macroscopic colonies in soft agar but did show microscopic abortive-looking colonies after 3 weeks in culture (see Figure 2e and Table 1 ). The expression of equivalent levels of ETV6-NTRK3 and mutated proteins in each of the cell lines was con®rmed by Western blot analysis (see Figure 2f ). These results indicate that the NTRK3 PTK region is crucial for transformation of NIH3T3 cells. Moreover, they demonstrate that ETV6-NTRK3 Y513 is essential for transformation while both Y517 and Y518 are required for full transformation.
ETV6-NTRK3 homodimerizes and heterodimerizes with wild-type ETV6
We predicted that ligand-independent dimerization of ETV6-NTRK3 was prerequisite for the PTK-mediated transformation activity of this oncoprotein. To begin to test this hypothesis, we co-incubated puri®ed GST-ETV6-NTRK3 fusion proteins with in vitro-translated ETV6-NTRK3 radiolabeled with 35 S-methionine. Glutathione beads were able to pull down labeled ETV6-NTRK3, but not in the absence of GST-ETV6-NTRK3 (see lanes 2 and 3, Figure 3a ). This indicated that ETV6-NTRK3 was capable of homodimerization. To test if this dimerization was mediated by the ETV6 HLH domain, we co-incubated puri®ed GST-ETV6-NTRK3 fusion proteins and in vitro-translated EN-DHLH mutant protein radiolabeled with 35 S-methionine and co-precipitated with glutathione beads. However, the EN-DHLH mutant could not be pulled down with glutathione beads indicating that the HLH domain is required for dimerization with ETV6-NTRK3 (see lane 2, Figure 3b ). As expected, the radiolabeled EN-DHLH mutant could not be pulled down when co-incubated with glutathione beads alone (see lane 3, Figure 3b ). Next we determined whether ETV6-NTRK3 is able to heterodimerize with wild-type ETV6. ETV6-NTRK3 and ETV6 were co-in vitro-translated in the presence of 35 S-methionine, and then subjected to immunoprecipitation using a-TrkC (C-14) antibody and protein A beads. As shown in Figure 3c (lane 2), ETV6 was coimmunoprecipitated along with ETV6-NTRK3 protein indicating that ETV6-NTRK3 can heterodimerize with ETV6. In contrast, ETV6 could not be pulled down when co-incubated with in vitro-translated EN-DHLH mutant (see lane 4, Figure 3c ). It was necessary to use unlabeled EN-DHLH in the latter experiment due to size overlap with ETV6; the presence of EN-DHLH in the reaction mixture was con®rmed by Western blotting using a-TrkC (C-14) antibody (see lane 6, Figure 3c ). These results provide strong evidence that ETV6-NTRK3 undergoes self-association and can heterodimerize with ETV6, and that these interactions are mediated by the ETV6 HLH domain.
ETV6-NTRK3 has PTK activity and undergoes tyrosine autophosphorylation
We wished to test our hypothesis that the ETV6-NTRK3 oncoprotein functions as a PTK. NIH3T3 cells expressing either ETV6-NTRK3, EN-Yx3F, EN-DHLH, the EN-K380N kinase inactive mutant, or mutants unable to associate with PLCg were analysed for tyrosine-speci®c phosphorylation. Whole cell lysates from cells grown in log phase were subjected to immunoprecipitation with a-TrkC (C-14) antibody, followed by immunoblot analysis with the antiphosphotyrosine antibody, RC-20. Immunoprecipitates showed tyrosine phosphorylation of ETV6-NTRK3 in transformed cells expressing ETV6-NTRK3 or the PLCg-binding mutants (see Figure 4a ). There was no evidence of ETV6-NTRK3 tyrosine phosphorylation in cells expressing the EN-K380N kinase inactive mutant or the EN-DHLH mutant. Interestingly, cells expressing EN-Yx3F also showed ETV6-NTRK3 tyrosine phosphorylation, possibly due to residual PTK activity or phosphorylation by other kinases (see Discussion). The presence of comparable amounts of immunoprecipitated ETV6-NTRK3 or mutant proteins in the samples was con®rmed by re-probing immunoblots with either a-ETV6:HLH antibodies (see Figure 4b) , or a-TrkC (C-14) to visualize EN-DHLH (data not shown). Similar results were obtained when a-ETV6:HLH instead of a-TrkC (C-14) was used for the initial immunoprecipitation step.
To con®rm that ETV6-NTRK3 is capable of auto-(or cross-) phosphorylation, ETV6-NTRK3, EN-DHLH, and EN-K380N were each in-vitro translated and subjected to immunoprecipitation with a-ETV6:HLH or a-TrkC (C-14), followed by immunoblotting using RC20. This revealed tyrosine phosphorylation of ETV6-NTRK3 but not of EN-DHLH or the EN-K380N kinase mutant (data not shown). These results provide evidence that ETV6-NTRK3 is a PTK capable of autophosphorylation, and that this activity requires an intact HLH domain and a functional PTK domain.
ETV6-NTRK3 binds PLCg but not SHC, GRB2, or PI-3K p85
NTRK3 is known to interact with speci®c cytoplasmic substrates which become tyrosine phosphorylated upon activation of the NTRK3 PTK domain. These interacting molecules include SHC (Guiton et al., 1995) , GRB2 (Bon®ni et al., 1996; Downward, 1996) , PI-3K (Barbacid, 1994; Hallberg et al., 1998; Obermeier et al., 1993b) , and PLCg as well as others (Berridge, 1993; Cockcroft and Thomas, 1992; Lee and Rhee, 1995; Nishizuka, 1995) . To determine if these molecules were involved in ETV6-NTRK3 signaling, we tested whether these molecules interacted with the ETV6-NTRK3 fusion protein. Sequence analysis of the ETV6-NTRK3 chimer predicted that the SHC, GRB2, and PI-3K interaction site (corresponding to NTRK3 Y516) is absent from the ETV6-NTRK3 protein due to the position of the fusion point, but that the PLCg site is retained (Knezevich et al., 1998b ). However, it was possible that other residues may mediate SHC, GRB2, and PI-3K binding to ETV6-NTRK3. To test this, lysates from ETV6-NTRK3 expressing cells grown in log phase were immunoprecipitated with either a-TrkC (C-14) or a-ETV6:HLH antibodies, and immunoblotted with antibodies against SHC, GRB2, PI-3K, or PLCg. As predicted by the structure of ETV6-NTRK3, only PLCg could be coimmunoprecipitated in these experiments ( Figure  5 ). PLCg was also found to associate with the tripletyrosine activation loop mutant, EN-Yx3F, but not with the EN-DHLH or EN-K380N mutants (Figures 5  and 6 ). We could ®nd no evidence of an interaction between SHC, GRB2, or PI-3K with ETV6-NTRK3 or any of the mutants, even though these molecules interacted with wild-type NTRK3 in control human medullary thyroid carcinoma cells overexpressing wildtype NTRK3 (Figure 5 ). These data suggest that, other than PLCg, ETV6-NTRK3 may interact with signaling molecules that are dierent than those normally associated with wild-type NTRK3.
To determine the role of PLCg-binding in the transformation activity of ETV6-NTRK3, NIH3T3 were infected with EN-Y628T, EN-Y628E, or EN-Y628Q recombinant retroviral vectors. The corresponding mutant proteins (see Figure 1 ) are predicted to lack the ability to bind PLCg, as phosphorylated ETV6-NTRK3 Y628 corresponds to the known PLCg binding site in NTRK3 (Y820) (Lamballe et al., 1993; Obermeier et al., 1993a) . All three puromycin-selected mutant-expressing cell lines still appeared fully transformed morphologically and were able to form macroscopic colonies in soft agar after 16 ± 19 days at levels similar to ETV6-NTRK3 (data not shown; Table  1 ). Immunoblot assays con®rmed that the EN-Y628T, EN-Y628E, and EN-Y628Q mutants were unable to associate with PLCg (see Figure 6 ). The expression of equivalent levels of ETV6-NTRK3 and mutated proteins in each of the cell lines was con®rmed by Western blot analysis (see lanes 4 ± 6, left panel, Figure   Figure 5 ETV6-NTRK3 interacts with PLCg but not with SHC, GRB2, or PI-3K p85 subunit. Whole cell lysates were prepared from a human medullary thyroid carcinoma cell line overexpressing wild-type NTRK3 (lane 1), as well as from NIH3T3 cells expressing ETV6-NTRK3 (lane 2), empty MSCVpac vector (lane 3), or EN-K380N (lane 4). Immunoprecipitation was performed with antibodies against the NTRK3 PTK domain followed by immunoblotting with antibodies directed against SHC, GRB2, PI-3K, or PLCg as indicated. Only wild-type NTRK3 was found to associate with SHC, GRB2, and PI-3K (lanes 1 of top three panels), while both NTRK3 and ETV6-NTRK3 bound PLCg (lanes 1 and 2 of bottom panel) Figure 6 Analysis of PLCg binding mutants for ability to associate with PLCg. Whole cell lysates were prepared from control human medullary thyroid carcinoma cells overexpressing wild-type NTRK3 (lane 1), or NIH3T3 cells (lanes 2 ± 9) expressing ETV6-NTRK3 or mutant constructs described in Materials and methods (see Figure 1 ). Lysates were subjected to immunoprecipitation with antibodies against the NTRK3 PTK domain followed by immunoblotting with a-PLCg antibodies. Lane 2, empty MSCVpac vector; lane 3, EN-DHLH; lane 4, ETV6-NTRK3; lane 5, EN-Yx3F; lane 6, EN-K380N; and lanes 7 ± 9, mutants with Y628 (corresponding to NTRK3 Y820 known to bind PLCg (Lamballe et al., 1993; Obermeier et al., 1993a) ) mutated to threonine, glutamic acid, or glutamine, respectively. The arrow shows the position of PLCg . These ®ndings, coupled with the fact that the ENYx3F activation loop mutant also bound PLCg even though it was non-transforming (see Figure 6 and Table 1 ), provides compelling evidence that binding and tyrosine phosphorylation of PLCg does not play a signi®cant role in transformation by the ETV6-NTRK3 oncoprotein.
ETV6-NTRK3-transformed NIH3T3 cells are tumorigenic in SCID mice
The above retrovirally infected NIH3T3 cells expressing either ETV6-NTRK3, the kinase inactive EN-K380N mutant, or vector alone were injected subcutaneously into severe combined immunode®cient (SCID) mice as described in the Materials and methods. ETV6-NTRK3-expressing NIH3T3 cells formed signi®cantly larger tumor masses than cells expressing EN-K380N (P=0.009) or vector alone (P=0.009). Mice injected with ETV6-NTRK3-expressing cells developed tumors averaging 3.15 g (n=5; see Table 2 ). On the other hand NIH3T3 cells expressing EN-K380N or vector alone did not form signi®cant tumor masses, with the respective average weights of the excised tissues at the sites of injection measuring 0.05 g (n=5) and 0.26 g (n=5), respectively (see Table 2 ).
Discussion
The CFS t(12;15)(p13;q25) chromosomal rearrangement creates a fusion gene encoding the ETV6 HLH domain linked to the tyrosine kinase domain of NTRK3 (Knezevich et al., 1998b) . Several other chimeric proteins involving the ETV6 HLH domain fused to a PTK domain have been described in human hematopoietic malignancies (Golub et al., 1994; Janssen et al., 1995; Lacronique et al., 1997; Peeters et al., 1997a) . As these fusion proteins have each been shown to be capable of transforming hematopoietic cells in vitro, we wanted to determine whether ETV6-NTRK3 has transformation activity. We chose to test this activity in NIH3T3 ®broblastic cells as the ETV6-NTRK3 gene fusion was originally identi®ed in CFS, which is thought to be of ®broblastic derivation (Knezevich et al., 1998b) . Interestingly, an ETV6-NTRK3 gene fusion identical to the one described for CFS was recently observed in an adult patient with AML (Eguchi et al., 1999) , although transformation studies were not reported. Our experiments demonstrated that ETV6-NTRK3 is a potent oncoprotein, as NIH3T3 cells expressing this molecule were morphologically transformed and readily grew macroscopic colonies in soft agar. Colony formation was of the same order of magnitude as NIH3T3 cells expressing the Ewing sarcoma EWS-FLI1 molecule, known to be a strong transforming protein (May et al., 1993) . Moreover, ETV6-NTRK3 expressing NIH3T3 cells were tumorigenic in SCID mice, which was not observed with cells expressing the PTK inactive EN-K380N mutant. These ®ndings indicate that ETV6-NTRK3 is a strong oncoprotein, and is the ®rst demonstration, to our knowledge, of an ETV6 fusion protein with transforming activity in NIH3T3 cells. We found that ETV6-NTRK3 transformation activity requires an intact HLH domain and that ETV6-NTRK3 is capable of homodimerization, both of which could be abrogated by deletion of the HLH domain. Moreover, absence of this domain eliminated ETV6-NTRK3 tyrosine phosphorylation as well as detectable PTK activity. We therefore hypothesize that the ETV6 HLH domain mediates ligand-independent homodimerization leading to autophosphorylation and activation of the ETV6-NTRK3 PTK. The ETV6 HLH domain has been shown to be required for homodimerization and subsequent autophosphorylation in fusions with ABL in AML and with PDGFRb in CMML (Carroll et al., 1996) . Moreover, ETV6 HLHdomain dependent dimerization has been demonstrated in fusions with Jak2 in ALL (Lacronique et al., 1997) which leads to constitutive Jak-Stat signaling (Ho et al., 1999) . ETV6-NTRK3 tyrosine phosphorylation most likely represents autophosphorylation activity of the chimeric protein based on several ®ndings. First, mutation of the lysine 380 ATP-binding site of ETV6-NTRK3 (mutant EN-K380N), corresponding to NTRK3 lysine 572 (Lamballe et al., 1991; Mitra, 1991) , completely abolished tyrosine phosphorylation of the fusion protein. Second, the non-dimerizing EN-DHLH mutant was not tyrosine phosphorylated in NIH3T3 cell lysates. Third, in-vitro translated ETV6-NTRK3 became tyrosine phosphorylated, while both EN-DHLH and the EN-K380N kinase inactive mutant were not tyrosine phosphorylated upon in vitro translation (data not shown).
EN-K380N did not transform NIH3T3 cells in our studies, indicating an essential role for functional PTK activity in ETV6-NTRK3 transformation. This is corroborated by detailed analysis of the PTK-encoding region of ETV6-NTRK3 fusion transcripts. Naturally occurring NTRK3 isoforms have been described which have 14, 25, or 39 amino acid inserts within the PTK domain adjacent to tyrosine autophosphorylation sites (reviewed in Barbacid, 1994) . These isoforms have low intrinsic PTK activity, fail to tyrosine phosphorylate SHC, SNT, and PLCg, and are defective in the biological responses they elicit (Guiton et al., 1995; Gunn-Moore et al., 1997; Lamballe et al., 1993; Tsoulfas et al., 1996) . We have found that ETV6-NTRK3 transcripts in CFS tumor cells lack these kinase inserts, consistent with the fully active PTK being involved in CFS-associated ETV6-NTRK3 gene fusions and in contrast to what was claimed in a recent report (Eguchi et al., 1999) . Consistent with this is the observation that the CFS-associated ETV6-NTRK3 protein is able to bind PLCg (see Figure 6 ).
To further investigate the role of tyrosine phosphorylation, we analysed the eects of tyrosine-to-phenylalanine mutations of the three predicted PTK activation loop tyrosines of ETV6-NTRK3, Y513, Y517 and Y518 (corresponding to NTRK3 Y705, Y709 and Y710, respectively) on NIH3T3 transformation. The activation loop tyrosines of wildtype NTRK3 reside within a conserved YSTDYYR sequence of the PTK domain and are essential for PTK activation (Barbacid, 1994) . The function of the ®rst conserved tyrosine (Y705) has yet to be determined, while Y709 and Y710 are thought to be responsible for NTRK3 autophosphorylation (Barbacid, 1994; Lamballe et al., 1993; Tsoulfas et al., 1993; Valenzuela et al., 1993) . Simultaneous mutation of all three tyrosines in ETV6-NTRK3 resulted in a nontransformed phenotype. Similarly, expression of the EN-ETV6-NTRK3 transforms NIH3T3 cells DH Wai et al Y513F mutant resulted in morphologically normal NIH3T3 cells and absence of macroscopic colonies in soft agar, indicating that this tyrosine is essential for transformation. EN-Y517F-or EN-Y518F-expressing cells each had a semi-transformed phenotype and exhibited markedly attenuated soft agar colony formation (see Figure 2e) . Therefore, while both appear to be required for full transformation, there may be redundancy between these two tyrosines in ETV6-NTRK3 mediated transformation.
Interestingly, we observed varying but consistent tyrosine phosphorylation of either EN-Yx3F, EN-Y513F, EN-Y517F, or EN-Y518F in cells expressing these proteins (see Figure 4 and data not shown), which is in contrast to analyses of NTRK1 (TRKA) where ligand-induced autophosphorylation of NTRK1 markedly decreases when the three activation loop tyrosines are mutated individually or in pairs (Cunningham et al., 1997) . There are several potential explanations for these ®ndings. First, it is possible that some level of autophosphorylation is maintained in the mutants (possibly through phosphorylation of Y628 and/or other tyrosines of ETV6-NTRK3), but that recruitment of essential substrates for transformation is abrogated by these mutations. Second, these mutant proteins may become tyrosine phosphorylated by other PTKs present in NIH3T3 cells, but still incapable of mediating essential phosphorylations required for transformation. A third possibility is that ETV6-NTRK3 phosphorylation does not play a role in its oncogenicity, and that other functions of the molecule are involved. More studies are necessary to con®rm the relationship between the three activation loop tyrosines and ETV6-NTRK3 phosphorylation. Taken together, however, our results are most consistent with a model in which ETV6-NTRK3 is a constitutively active PTK capable of autophosphorylation, although we have not absolutely ruled out that ETV6-NTRK3 is a substrate for another PTK.
NT-3 induced PTK activation of wild-type NTRK3 results in the direct association and tyrosine phosphorylation of several downstream signaling molecules including SHC, GRB2, the PI-3K p85 subunit, and PLCg (Barbacid, 1994) as well as SNT (Peng et al., 1995; Rabin et al., 1993) . This leads to activation of multiple pathways involved in NTRK3 signaling, including the RAS-RAF1 pathway (Bon®ni et al., 1996; Downward, 1996) , PI-3K activation of the cell survival mediator, Akt/PKB (Barbacid, 1994; Hallberg et al., 1998; Obermeier et al., 1993b) , and the PKC pathway (Berridge, 1993; Cockcroft and Thomas, 1992; Lee and Rhee, 1995; Nishizuka, 1995) . However, the binding site for SHC/GRB2 and PI-3K p85, NTRK3 tyrosine-516 (Hallberg et al., 1998) , is lost from the NTRK3 portion of the ETV6-NTRK3 fusion protein due to the position of the breakpoint (Knezevich et al., 1998b) . In keeping with this, we were unable to demonstrate any association of either SHC, GRB2, or PI-3K p85 with ETV6-NTRK3. However, this does not rule out a role for the RAS-RAF1 pathway in ETV6-TRK3 mediated transformation. It is possible that SHC (and therefore the RAS/RAF1 pathway) might be activated indirectly without binding to the fusion oncoprotein. Alternatively, other adaptor molecules may be involved in RAS activation; several newly described molecules have been shown to interact with activated NTRK3 and to be potentially involved in NTRK3 signaling, including rAPS and SH2-Bb (Qian et al., 1998) . Recent reports have also described interactions between the related receptor, NTRK1, and the GRB2-associated binder-1 docking protein (Gab1) (Holgado-Madruga et al., 1997) , and between NTRK1 and caveolin in PC12 cells exposed to NGF (Bilderback et al., 1999) . Their potential involvement in ETV6-NTRK3 signaling is currently being studied.
We found that ETV6-NTRK3 is able to bind and tyrosine phosphorylate PLCg, as predicted by the presence of carboxy-terminal Y628 in the chimeric protein. This residue corresponds to NTRK3 Y820, which is known to bind PLCg (Lamballe et al., 1993; Obermeier et al., 1993a) . However, expression of three dierent ETV6-NTRK3 constructs with mutations of Y628 to threonine, glutamic acid, or glutamine, NTRK3 nt 1601-1620 CC TCT TAA TGT GCT GCA CAT m1164F GTG GCT GTG AAC GCC CTG AAG GAT CCC m1164R GGG ATC CTT CAG GGC GTT CAC AGC CAC m1562F C GGC ATG TCC AGA GAT GTC TTC AGC ACG G m1562R C CGT GCT GAA GAC ATC TCT GGA CAT GCC G m1574F GTC TAC AGC ACG GAT TTT TAC AGG GTG GGA GG m1574R CC TCC CAC CCT GTA AAA ATC CGT GCT GTA GAC m1577F C AGC ACG GAT TAT TTC AGG GTG GGA GGA CAC m1577R GTG TCC TCC CAC CCT GAA ATA ATC CGT GCT G mtyrx3F TCC AGA GAT GTC TTC AGC ACG GAT TTT TTC AGG GTG GGA GGA CAC mtyrx3R GTG TCC TCC CAC CCT GAA AAA ATC CGT GCT GAA GAC ATC TCT GGC Y628T-for G GCC ACC CCA ATC ACC CTG GAC ATT CTT GGC Y628T-rev GCC AAG AAT GTC CAG GGT GAT TGG GGT GGC C Y628E-for G GCC ACC CCA ATC GAG CTG GAC ATT CTT GGC Y628E-rev GCC AAG AAT GTC CAG CTC GAT TGG GGT GGC C Y628Q-for G GGC ACC CCA ATC CAG CTG GAC ATT CTT GGC Y628Q-rev GCC AAG AAT GTC CAG CTG GAT TGG GGT GGC C ETV6-NTRK3 transforms NIH3T3 cells DH Wai et al respectively, each transformed NIH3T3 cells to the same degree as non-mutated ETV6-NTRK3 (Table 1) , even though there was no detectable association of these mutant proteins with PLCg in immunoprecipitation experiments. These results provide preliminary evidence that ETV6-NTRK3-induced transformation does not require PLCg activation and thus is likely not mediated through the PKC pathway. In keeping with this interpretation, the activation loop tyrosine mutant EN-Yx3F also bound PLCg even though it was nontransforming ( Figure 6 ). More detailed analyses are required to test the role of PKC activation in ETV6-NTRK3 transformed cells. An intriguing possibility is that ETV6-NTRK3 recruits components of potentially novel signaling pathways not involving RAS-RAF1 activation or functioning downstream of RAS-RAF1. We are currently evaluating the role of the RAS-RAF1 pathway in ETV6-NTRK3 signaling as well as searching for novel ETV6-NTRK3 associating molecules. Interestingly, we observed in vitro heterodimerization between ETV6-NTRK3 and wild-type ETV6. It is possible that binding of ETV6-NTRK3 to ETV6 depletes levels of the latter, which has been hypothesized to function at least in part as a tumor suppressor (Poirel et al., 1998) . ETV6 is known to be a phosphoprotein , and so may be a substrate for ETV6-NTRK3; however, we found no evidence of ETV6 tyrosine phosphorylation by ETV6-NTRK3 in these studies (data not shown). Alternatively, heterodimerization with other HLHcontaining molecules may lead to the recruitment and activation of, as yet, unidenti®ed signaling pathways. Subcellular localization studies suggest that ETV6-NTRK3 resides predominantly in the cytoplasm, but it is also observed at low levels in the nucleus (unpublished results). Further studies are required to determine the signi®cance of these ®ndings.
Materials and methods
Generation of full-length ETV6-NTRK3
Full-length ETV6-NTRK3 was constructed by splicing a partial ETV6-NTRK3 fragment to wild-type ETV6. The partial ETV6-NTRK3 fragment was isolated by digesting a 3'-RACE PCR product obtained from a CFS tumor (Knezevich et al., 1998b) , cloned into pCR TM 2.1 (Invitrogen), with PvuII and NotI. This fragment contained nucleotides 826 to 1033 of ETV6 cDNA fused in-frame to the 3'-end of NTKR3 cDNA at nucleotide 1601. Full-length ETV6, cloned into pGEM-3Z (a generous gift of P Marynen, University of Leuven, Leuven, Belgium), was digested with EcoRI and PvuII to generate a fragment containing the ®rst 825 base pairs of ETV6 cDNA. These two products were directionally ligated into pBluescript II KS at the EcoRI and NotI sites to produce the 2106-bp ETV6-NTRK3 fusion cDNA. All restriction endonucleases were obtained from New England Biolabs. Full-length clones were screened by DNA sequencing and PCR using TEL541 and Trk2 primers. All primer sequences are described in Table 3 . PCR obtained the expected 731-bp product using the following conditions: 948C for 1.5 min, followed by 35 cycles of 948C for 1 min, 608C for 1 min, and 728C for 1 min, and a ®nal extension of 728C for 10 min. DNA sequencing used ETV6 primers TEL352 and TEL701, NTRK3 primers Trk1 and Trk3, and standard primers T3 and T7. All sequencing was performed on an ABI373A DNA Sequencer (Applied Biosystems) and analysed using DNA-STAR TM software.
ETV6-NTRK3 HLH-deletion mutant (EN-DHLH)
A fusion protein mutant lacking a functional ETV6 helix ± loop ± helix (HLH) domain was constructed by using BspMI and EcoNI to delete a large portion of the HLH domain (ETV6 amino acid residues 64 ± 117). This generated a 1950-bp EN-DHLH construct which lacked nucleotides 193 ± 351 of ETV6 (Figure 1 ). Clones were screened by PCR using TEL114 and TEL541rev primers (Table 3) , followed by cDNA sequencing to con®rm correct sequences and orientation.
Site-directed mutagenesis
The QuikChange TM Site-Directed Mutagenesis Kit (Stratagene) was used to introduce point mutations within the NTRK3 portion of the 2106-bp fusion cDNA in pBluescript II KS. Three primer sets (m1562F/m1562R, m1574F/m1574R, and m1577F/m1577R; Table 3 ) were used in the site-directed mutagenesis (SDM) of the three activation loop tyrosines (Y705, Y709, and Y710 of NTRK3) (Barbacid, 1994; Lamballe et al., 1993; Tsoulfas et al., 1993; Valenzuela et al., 1993) to phenylalanines, resulting in EN-Y513F, EN-Y517F, and EN-Y518F mutants, respectively. An ETV6-NTRK3 triple Y513F, Y517F, and Y518F mutant (called EN-Yx3F), was made using mtyrx3F and mtyrx3R primers (Figure 1 ; Table 3 ). An ETV6-NTRK3 PTK-inactive mutant replacing the ATP-binding lysine 380 (NTRK3 K572) (Lamballe et al., 1991; Mitra, 1991) with asparagine, designated EN-K380N, was made using m1164F and m1164R primers (Figure 1 ; Table 3 ). Finally, ETV6-NTRK3 tyrosine 628 (NTRK3 tyrosine 820) was converted to either a threonine (EN-Y628T), glutamic acid (EN-Y628E), or glutamine (EN-Y628Q) residue to ablate this amino acid as the putative binding site for phospholipase-Cg (Lamballe et al., 1993; Obermeier et al., 1993a) . Three sets of primer pairs were employed to create these respective mutants: Y628T-for/ Y628T-rev, Y628E-for/Y628E-rev, and Y628Q-for/Y628Q-rev (Figure 1 ; Table 3 ). SDM-PCR conditions for all primers were as follows: 958C for 30 s, followed by 12 cycles of 958C for 30 s, 558C for 1 min, and 688C for 10 min 15 s. DNA sequencing of the inserts was used to con®rm the point mutations; sequences using standard primer T7 and NTRK3 primer PS2 were obtained and analysed as described above.
Retroviral vectors
cDNAs encoding wild-type or mutated forms of ETV6-NTRK3 were inserted into the retroviral vector MSCVpac (Hawley et al., 1994) at the EcoRI site. Plasmid DNA of the retroviral vectors was transfected into the BOSC23 ecotropic retroviral packaging cell line (Pear et al., 1993) , using calcium phosphate precipitation as described (Pear et al., 1993) . The retrovirus-containing supernatants were collected from the BOSC cells 48 h after transfection and used to infect NIH3T3 cells.
Soft agar assays
Soft agar assays were performed according to established protocols (May et al., 1993) . NIH3T3 cells infected with recombinant retroviruses carrying either empty vector, ETV6-NTRK3, or one of the above mutants were plated in quadruplicate at a density of 30 000 cells per 6-cm tissue culture dish. The NIH3T3 cells were suspended in soft agar (16IMDM, 10% calf serum, and 0.7% agar noble). Macroscopic colonies were counted (in quadruplicate) and the plates were photographed 16 to 19 days after plating, and they were observed for up to 28 days for macroscopic colony growth.
SCID mice studies
Pathogen free female C.B-17 scid/scid (SCID) mice, 5 ± 6 weeks old, tested for leakiness, were obtained from ETV6-NTRK3 transforms NIH3T3 cells DH Wai et al Bomholtgard Breeding and Research Center (Ry, Denmark) and were injected subcutaneously (s.c.) into the left lower ank with 10 7 NIH3T3 cells transfected with control vector, a ETV6-NTRK3 kinase-de®cient mutant (EN-K380N) or ETV6-NTRK3 (n=5/group). The animals were housed in laminar¯ow racks and microisolator cages under speci®c pathogen free conditions and received autoclaved food and water. SCID mice were evaluated for tumor growth and organ involvement 11 days after injection, a time point at which tumor growth in the ETV6-NTRK3 group necessitated the termination of the experiment. Statistical signi®cance of dierences in tumor weight in the respective groups was evaluated using the Mann-Whitney U-Test. P values of 50.05 were considered to be of statistical signi®cance.
Production of GST-ETV6-NTRK3 fusion proteins
Glutathione-S-transferase (GST) ETV6-NTRK3 fusion proteins expressed in Sf9 cells were generated from full-length ETV6-NTRK3 cDNA using the BaculoGold Expression and Puri®cation kit (Pharmingen), following the manufacturer's protocols. Recombinant protein was puri®ed by glutathione column chromatography for subsequent protein studies.
Antibodies
Antibodies used for immunoprecipitation included a-TrkC (C-14) (Santa Cruz Biotechnology) (2 mg/ml) and a-ETV6:HLH (a gift of Dr P Marynen, University of Leiden) (1 : 500 dilution). Antibodies used for immunoblot analysis included a-phosphotyrosine (RC20-Horse Radish Peroxidase conjugated 
Immunoprecipitation and immunoblotting
Lysates of PBS-washed NIH3T3 cells expressing the above constructs were prepared, immunoprecipitated and analysed by immunoblotting as previously described (Obermeier et al., 1993b) . Brie¯y, T25-¯asks containing 70 ± 90% con¯uent cells were lysed in 1 ml of lysis buer (1.5 mM MgCl 2 , 150 mM NaCl, 50 mM HEPES, 10 mM NaF, 10 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 2 mM EDTA, 2 mM NaMoO 4 ×2H 2 O, 10% Glycerol, 0.5 ± 1.0% Nonidet P-40, Leupeptin (10 mg/ml), Aprotinin (10 mg/ml), and freshly prepared PMSF (250 mM)) on ice for 15 min. Lysates were cleared by centrifugation at 12 000 g for 10 min prior to immunoprecipitation for 2 h with the relevant antibody. Washed immunoprecipitates were then mixed with Laemmli buer and electrophoresed overnight on 10 ± 15% SDS-polyacrylamide gels according to standard methods. Electrophoresed proteins were transferred to Immobilon-P (Millipore) prior to immunoblot analysis with the indicated antibodies. Proteins were visualized with ECL (Amersham) according to the manufacturer's protocols.
Oligomerization studies
To determine whether ETV6-NTRK3 heterodimerizes with wildtype ETV6, both ETV6 and ETV6-NTRK3 were cotranslated with the TNT T7/T3 Coupled Reticulocyte Lysate System (Promega) according to the manufacturer's instructions. Complexes were immunoprecipitated as described previously (Lacronique et al., 1997) with a-TrkC (C-14) or a-ETV6:HLH antibodies. Immunoprecipitates were analysed by immunoblotting with a-ETV6:HLH or a-TrkC (C-14) , respectively, and visualized as described above. To test for ETV6-NTRK3 homodimerization, 5 mg of puri®ed GST-ETV6-NTRK3 recombinant protein was mixed with 35 SMethionine-labeled (Amersham) in vitro translated ETV6-NTRK3, immunoprecipitated with glutathione beads, and electrophoresed as above. The resolving gel was dried and exposed to XAR-5 ®lm for 16 h.
